Sri Lanka NMRA Aesthetic Device Classes and 2027 Deadline

Sri Lanka's National Medicines Regulatory Authority (NMRA) has identified specific devices used to modify appearance or anatomy for aesthetic purposes, assigned them to Classes IIa, IIb, or III, and granted a one-year grace period for registration until 23 July 2027.

The one-page NMRA notice was signed on 23 July 2026 and posted on the authority's website on 28 July 2026. It is an administrative notice on product categories, classification rules, and the registration grace period. It should not be described as a new statute or a complete replacement for Sri Lanka's existing medical-device framework.

View the announcement on the NMRA website and open the signed notice.

The classifications in the NMRA notice

This matrix is the most important operational part of the notice. “Aesthetic device” is not one risk class in Sri Lanka. The stated class changes with invasiveness, implantation, injection, and energy delivery.

Which products are expressly covered

NMRA lists four broad groups:

• any implant for modification of any body part;
• any injectable dermal filler or mucous membrane filler;
• instruments, apparatus, implements, machines, or appliances intended to remove or degrade fat by invasive means; and
• instruments, apparatus, appliances, software, materials, or other articles—used alone or in combination, including software necessary for proper application—intended for laser procedures, microneedling, ultrasonic cavitation, HIFU tightening, or Fraxel radiofrequency technology for skin tightening.

The wording reaches more than the energy-delivery console. It expressly includes necessary software and articles used alone or in combination. Manufacturers of platforms with applicators, handpieces, control software, or multiple treatment modes should therefore assess the regulated system and each marketed configuration, not only the main hardware SKU.

The notice does not classify every possible beauty or cosmetic product. It identifies the categories and technologies above. A product outside that text should not be pulled into scope solely because it is sold to an aesthetic clinic; its intended purpose, mode of action, and the NMRA medical-device definition still require separate analysis.

What the 23 July 2027 grace period does—and does not say

The notice states: “A one year grace period is hereby granted, until 23rd July 2027 for the registration of the above mentioned devices.” That is the verified deadline.

The notice does not separately state:

• an enforcement start date after the grace period;
• whether submission alone, rather than completed registration, is sufficient by the deadline;
• how NMRA will treat applications still under evaluation on 23 July 2027;
• whether an existing registration under another category must be amended; or
• a special dossier, fee, or expedited route for these products.

Those gaps should not be filled with assumptions. A manufacturer whose timing depends on one of them should obtain a case-specific answer from NMRA through its Sri Lankan Marketing Authorization Holder or local regulatory representative.

How the notice fits into Sri Lanka's existing registration system

NMRA's official Medical Devices page says medical devices within the statutory definition should be registered with the authority and licensed for relevant activities including manufacture, importation, repackaging, sale, and distribution. It also says a foreign manufacturer submits through a Sri Lankan Marketing Authorization Holder (local agent) that is responsible for registration, licensing, importation, distribution, quality failures, and other local regulatory matters for the device.

The same official page describes the current dossier-acceptance process: applicants complete the specified online form, assemble the required checklist and supporting documentation, and submit the dossier physically at NMRA's accepting point. Incomplete submissions are not accepted for evaluation. The new aesthetic-device notice does not displace that process or create an alternative online-only route.

For manufacturers, the classification table should therefore feed directly into the existing registration workstream: application strategy, evidence expectations, local-agent coordination, dossier preparation, fees, and submission timing.

Portfolio implications by technology

The classification differences create different planning priorities within one aesthetic portfolio:

• Implants and injectable fillers: NMRA assigns Class III. These products should not inherit the strategy for a non-invasive platform merely because both are sold for appearance modification.
• Laser, RF, HIFU, and cavitation platforms: the notice assigns Class IIb under Rule 9. Multi-energy systems should be mapped mode by mode so the submitted configuration and intended uses are explicit.
• Microneedling: the listed devices are Class IIa under Rule 6. A combined microneedling/RF platform may engage more than the microneedling line of the table and should be confirmed with NMRA.
• Invasive fat removal: the class can be IIa or IIb under Rules 6 or 7, with Rule 9 added when the device is energy-based. The notice itself therefore requires a more granular determination than assigning one class to every fat-removal product.

These are not merely taxonomy differences. Class drives the evidence and review strategy, and technology combinations can change which rule controls. The safest portfolio plan is a product-level matrix showing intended purpose, invasiveness, energy modality, components/software, applicable rule, proposed class, current registration status, and owner.

What manufacturers, importers, and local agents should do

1. Build the in-scope inventory from the notice's exact product language. Include accessories, software, handpieces, and marketed combinations where they are part of proper application.
2. Assign the stated rule and class product by product. Do not use a single “aesthetic” classification across implants, fillers, energy devices, and microneedling.
3. Identify ambiguous multi-mode systems early. Seek NMRA confirmation where a product spans two rows of the table or where Rule 9 may change the result.
4. Reconcile existing registrations and applications. Confirm whether the product, intended purpose, model grouping, and classification currently on file match the notice.
5. For foreign manufacturers, coordinate through the Sri Lankan Marketing Authorization Holder. The local agent owns critical registration and licensing responsibilities under NMRA's published process.
6. Work backward from 23 July 2027. The notice grants time for registration, not a guarantee of review completion within a particular period. Build time for classification questions, document gaps, dossier acceptance, and NMRA requests.
7. Document any NMRA clarification. Because the notice is brief, product-specific answers may become the most important evidence in the submission strategy.

For a wider comparison of how the same filler or energy-based platform can move between risk classes in different markets, see Pure Global's Aesthetic Device Global Market Access 2026.

The key takeaway is narrow but consequential: Sri Lanka has now published an explicit classification matrix for the listed aesthetic technologies and a registration grace period ending 23 July 2027. The right response is not to treat the whole sector as one category, but to segment the portfolio by technology and risk, confirm edge cases, and move each product through NMRA's existing registration process with enough time to resolve dossier questions before the deadline.